Insulin degludec

A long-acting modern insulin analogue with a predictable pharmacokinetic/ pharmacodynamic profile

Marc Rendell

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Insulin degludec is, like insulin detemir, a product of coupling of Des-B30 threonine insulin to fatty acid side chains. After injection, degludec self associates, precipitating in subcutaneous tissue. There is a continuous and highly predictable slow dissociation of insulin monomers from this depot; insulin levels rise immediately reaching tmax at 10-12 hours, followed by a slow decline with a t1/2 of 17-21 hours, roughly double the duration of action of insulin glargine. An important property of degludec not shared by glargine is miscibility with rapid-acting insulin. Although the effect of coadministered insulin aspart is somewhat blunted by coformulation with degludec, a preparation of 70% degludec and 30% aspart has predictable pharmacodynamics. Daily administration of degludec has glucose-lowering benefits not different from those of glargine, with purportedly less hypoglycemia. Although degludec is approved and marketed in Europe under the brand name Tresiba®, the U.S. Food and Drug Administration, in a surprising development, challenged the assertion of lower tendency to hypoglycemia with degludec, and, more importantly, raised concerns that degludec may have a higher cardiovascular risk than glargine. Only a long-term study in a large patient population can resolve these questions. However, release of degludec for marketing to appropriate patients should proceed while awaiting the results of such a study.

Original languageEnglish
Pages (from-to)387-397
Number of pages11
JournalDrugs of Today
Volume49
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Long-Acting Insulin
Pharmacokinetics
Hypoglycemia
Insulin Aspart
Short-Acting Insulin
insulin degludec
Insulin
Subcutaneous Tissue
Threonine
United States Food and Drug Administration
Marketing
Names
Fatty Acids

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Insulin degludec : A long-acting modern insulin analogue with a predictable pharmacokinetic/ pharmacodynamic profile. / Rendell, Marc.

In: Drugs of Today, Vol. 49, No. 6, 06.2013, p. 387-397.

Research output: Contribution to journalReview article

@article{fbbe0818c0c94f04893b75675a57448d,
title = "Insulin degludec: A long-acting modern insulin analogue with a predictable pharmacokinetic/ pharmacodynamic profile",
abstract = "Insulin degludec is, like insulin detemir, a product of coupling of Des-B30 threonine insulin to fatty acid side chains. After injection, degludec self associates, precipitating in subcutaneous tissue. There is a continuous and highly predictable slow dissociation of insulin monomers from this depot; insulin levels rise immediately reaching tmax at 10-12 hours, followed by a slow decline with a t1/2 of 17-21 hours, roughly double the duration of action of insulin glargine. An important property of degludec not shared by glargine is miscibility with rapid-acting insulin. Although the effect of coadministered insulin aspart is somewhat blunted by coformulation with degludec, a preparation of 70{\%} degludec and 30{\%} aspart has predictable pharmacodynamics. Daily administration of degludec has glucose-lowering benefits not different from those of glargine, with purportedly less hypoglycemia. Although degludec is approved and marketed in Europe under the brand name Tresiba{\circledR}, the U.S. Food and Drug Administration, in a surprising development, challenged the assertion of lower tendency to hypoglycemia with degludec, and, more importantly, raised concerns that degludec may have a higher cardiovascular risk than glargine. Only a long-term study in a large patient population can resolve these questions. However, release of degludec for marketing to appropriate patients should proceed while awaiting the results of such a study.",
author = "Marc Rendell",
year = "2013",
month = "6",
doi = "10.1358/dot.2013.49.6.1976051",
language = "English",
volume = "49",
pages = "387--397",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "6",

}

TY - JOUR

T1 - Insulin degludec

T2 - A long-acting modern insulin analogue with a predictable pharmacokinetic/ pharmacodynamic profile

AU - Rendell, Marc

PY - 2013/6

Y1 - 2013/6

N2 - Insulin degludec is, like insulin detemir, a product of coupling of Des-B30 threonine insulin to fatty acid side chains. After injection, degludec self associates, precipitating in subcutaneous tissue. There is a continuous and highly predictable slow dissociation of insulin monomers from this depot; insulin levels rise immediately reaching tmax at 10-12 hours, followed by a slow decline with a t1/2 of 17-21 hours, roughly double the duration of action of insulin glargine. An important property of degludec not shared by glargine is miscibility with rapid-acting insulin. Although the effect of coadministered insulin aspart is somewhat blunted by coformulation with degludec, a preparation of 70% degludec and 30% aspart has predictable pharmacodynamics. Daily administration of degludec has glucose-lowering benefits not different from those of glargine, with purportedly less hypoglycemia. Although degludec is approved and marketed in Europe under the brand name Tresiba®, the U.S. Food and Drug Administration, in a surprising development, challenged the assertion of lower tendency to hypoglycemia with degludec, and, more importantly, raised concerns that degludec may have a higher cardiovascular risk than glargine. Only a long-term study in a large patient population can resolve these questions. However, release of degludec for marketing to appropriate patients should proceed while awaiting the results of such a study.

AB - Insulin degludec is, like insulin detemir, a product of coupling of Des-B30 threonine insulin to fatty acid side chains. After injection, degludec self associates, precipitating in subcutaneous tissue. There is a continuous and highly predictable slow dissociation of insulin monomers from this depot; insulin levels rise immediately reaching tmax at 10-12 hours, followed by a slow decline with a t1/2 of 17-21 hours, roughly double the duration of action of insulin glargine. An important property of degludec not shared by glargine is miscibility with rapid-acting insulin. Although the effect of coadministered insulin aspart is somewhat blunted by coformulation with degludec, a preparation of 70% degludec and 30% aspart has predictable pharmacodynamics. Daily administration of degludec has glucose-lowering benefits not different from those of glargine, with purportedly less hypoglycemia. Although degludec is approved and marketed in Europe under the brand name Tresiba®, the U.S. Food and Drug Administration, in a surprising development, challenged the assertion of lower tendency to hypoglycemia with degludec, and, more importantly, raised concerns that degludec may have a higher cardiovascular risk than glargine. Only a long-term study in a large patient population can resolve these questions. However, release of degludec for marketing to appropriate patients should proceed while awaiting the results of such a study.

UR - http://www.scopus.com/inward/record.url?scp=84880009335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880009335&partnerID=8YFLogxK

U2 - 10.1358/dot.2013.49.6.1976051

DO - 10.1358/dot.2013.49.6.1976051

M3 - Review article

VL - 49

SP - 387

EP - 397

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - 6

ER -